Abstract Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6is) in combination with Endocrine
Therapy (ET) represent the standard frontline therapy for patients with Hormone Receptor …

Aim Accurate evaluation of glomerular filtration rate (GFR) is crucial in Oncology as drug
eligibility and dosing depend on estimates of GFR. However, there are no clear guidelines …

Besides true acute kidney injury (AKI), the occurrence of pseudo-AKI has been associated
with several targeted agents. To improve the management of cancer patients treated with …

Cancer drugs and acute kidney injury: new therapies and new challenges Page 1 MNH 330503
CURRENT OPINION Cancer drugs and acute kidney injury: new therapies and new challenges …

Understanding the pharmacokinetics of gentamicin is essential in special populations, such
as pediatric patients with acute lymphoblastic leukemia (ALL), in light of previous studies …

Maternal health during pregnancy has a direct impact on the risk and severity of
neurodevelopmental disorders (NDDs) in the offspring, especially in the case of drug …

Diabetes mellitus with cardiovascular diseases is often a multi-systemic disease that
requires a multi-therapeutic approach which mostly poses a challenge to laboratory result …

Background Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have improved the
efficacy of endocrine therapy in hormone receptor-positive (HR+)/human epidermal growth …

Various classes of targeted therapies have emerged in the last few years, which have
revolutionized cancer treatment, and improved the prognosis and survival of cancer patients …

Lung cancer has historically posed a significant challenge in the field of oncology, with
limited treatment options and often a poor prognosis. Nevertheless, the standard treatment …